A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

William Kielbasa; Krista M Phipps; James Tseng; Fanni Natanegara; Eden Cheng; Scott A. Monk; Christoffer Bundgaard; Donnelly B. Kevin; Hugh Norman Nuthall; Nicholas McDonald; Peter Lindsay‐Scott; Nicolas Dreyfus; Mai Khanh Hawk; Susan Warner; Kevin Biglan; Julie A. Gilmore; Xiaoyu Zhang; Dustin J. Mergott; Stephen L. Lowe

Journal ArticleOPEN ACCESS

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

Kielbasa W
Phipps K
Tseng J
et al.

Alzheimer's & Dementia (2020) 16(S9)

DOI: 10.1002/alz.040473

N/ACitations

6Readers

Abstract

Background: LY3372689, an O-GlcNAcase (OGA) enzyme inhibitor, is being developed

Cite

CITATION STYLE

APA

Kielbasa, W., Phipps, K. M., Tseng, J., Natanegara, F., Cheng, E., Monk, S. A., … Lowe, S. L. (2020). A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme. Alzheimer’s & Dementia, 16(S9). https://doi.org/10.1002/alz.040473

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

Abstract

Cite

Register to see more suggestions